GERN
NEUTRALAt a glance
Key valuation, profitability, growth, and risk metrics.
AI Analysis
AI-powered fundamental assessment
Key Strengths
Key Risks
Performance Snowflake
Multi-dimensional analysis across 5 key categories
Trades at a premium to book value; valuation is based on future expectations rather than current assets or earnings.
- Forward P/E of 22.00 suggests a path to profitability
- High P/B ratio of 4.99
- High P/S ratio of 6.13
- No Graham Number due to lack of earnings
Future value is tied to the transition from R&D to commercial revenue.
- Positive EPS growth trends
- Strong analyst target price ($3.40)
- Recent 1Y price appreciation of 26.6%
- Revenue growth is nearly flat at 1%
Historical performance is defined by continuous capital burn.
- Consistent ability to beat earnings estimates recently
- 25 consecutive quarters of negative earnings
- Long-term 3Y price decline of 12.9%
While the balance sheet has cash (liquidity), the operational health (Piotroski) is non-existent.
- Very high Current Ratio (4.66)
- Low Debt/Equity (0.54)
- Piotroski F-Score of 0/9
- Negative ROE and ROA
Company is in a growth/burn phase; dividends are not applicable.
- No dividend paid
- 0/100 dividend strength
Stock Price & Analyst Targets
Real-time price movements and analyst price targets
Multi-Horizon Performance vs Peers
Price momentum across 5Y → 1W horizons for GERN and closest competitors.
| Company | 5Y | 3Y | 1Y | 6M | 1M | 1W |
|---|---|---|---|---|---|---|
|
GERN
Geron Corporation
Primary
|
+23.9% | -12.9% | +26.6% | +26.6% | +8.0% | +6.0% |
|
BFLY
Butterfly Network, Inc.
Peer
|
-76.9% | +59.4% | +8.9% | +128.9% | +14.2% | +8.4% |
|
EYPT
EyePoint, Inc.
Peer
|
+41.6% | +326.8% | +243.1% | +2.1% | -9.6% | +8.8% |
|
ALVO
Alvotech
Peer
|
-65.9% | -71.8% | -66.2% | -52.0% | -17.7% | -1.6% |
|
BLFS
BioLife Solutions, Inc.
Peer
|
-40.8% | -0.5% | -10.7% | +10.1% | -2.1% | +1.8% |
Positive values indicate cumulative gains over the specified period. Comparables pulled from the same sector to highlight whether momentum is stock-specific or industry-wide.
Historical Performance Trends
Long-term financial metrics and growth patterns
Revenue & Net Income
Profit & Operating Margins
Return on Equity (ROE)
Quarterly Revenue Growth
Valuation Metrics
Key valuation ratios and pricing indicators
Profitability
Profit margins and return metrics
Growth
Revenue and earnings growth rates
Financial Health
Balance sheet strength and liquidity metrics
Financial Statement Flow
Interactive flow visualization showing how money moves through the company Q4 2025
Quarterly Earnings History
EPS performance vs analyst estimates
Healthcare Sector Comparison
Similar Companies
Peer comparison within the same industry
| Company | AI Rating | Market Cap | P/E | ROE | Profit Margin | Price | |
|---|---|---|---|---|---|---|---|
|
GERN
Geron Corporation
|
NEUTRAL | $1.13B | - | -33.0% | -45.4% | $1.76 | |
|
BFLY
Butterfly Network, Inc.
|
NEUTRAL | $1.14B | - | -41.4% | -90.3% | $4.51 | Compare |
|
EYPT
EyePoint, Inc.
|
NEUTRAL | $1.18B | - | -72.2% | -% | $14.17 | Compare |
|
ALVO
Alvotech
|
BEARISH | $1.19B | 16.61 | -% | 12.1% | $3.82 | Compare |
|
BLFS
BioLife Solutions, Inc.
|
NEUTRAL | $1.2B | - | -5.2% | -3.2% | $24.87 | Compare |
Recent Insider Trading
Insider buy and sell transactions from the last 6 months
| Date | Insider | Position | Transaction | Shares | Value |
|---|---|---|---|---|---|
| 2026-03-31 | SPIEGEL ROBERT J | Director | Stock Award | 5,243 | $7,812 |
| 2026-02-18 | ROBERTSON MICHELLE | Chief Financial Officer | Sale | 9,855 | $19,119 |
| 2026-02-18 | ROBERTSON MICHELLE | Chief Financial Officer | Stock Award | 27,500 | - |
| 2025-12-31 | SPIEGEL ROBERT J | Director | Stock Award | 5,918 | $7,812 |
Wall Street Analysts
Professional analyst ratings and price targets
Past News Coverage
Recent headlines mentioning GERN from our newsroom.